Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hayward

Showing results (361-370 of 364) with videos related to

Pageof 37
Sort By:
You have reached the last page of results.This site can display upto 364 results.
Scientific Reports|February 27, 2025
The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinomaWilliam P Katt, Cheryl E Balkman, Scott D Butler, et al.
Journal of Neuromuscular Diseases|February 6, 2026
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH studyNicol C Voermans, Jeffrey M Statland, Lawrence J Hayward, et al.
Molecular Cancer Therapeutics|October 13, 2010
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibodyAngela Coxon, James Bready, Hosung Min, et al.
The Lancet. Neurology|April 17, 2024
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trialRabi Tawil, Kathryn R Wagner, Johanna I Hamel, et al.
Pageof 37

Showing results (361-370 of 364) with videos related to

Sort By:
Pageof 37
You have reached the last page of results.This site can display upto 364 results.
Scientific Reports|February 27, 2025
The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinomaWilliam P Katt, Cheryl E Balkman, Scott D Butler, et al.
Journal of Neuromuscular Diseases|February 6, 2026
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH studyNicol C Voermans, Jeffrey M Statland, Lawrence J Hayward, et al.
Molecular Cancer Therapeutics|October 13, 2010
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibodyAngela Coxon, James Bready, Hosung Min, et al.
The Lancet. Neurology|April 17, 2024
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trialRabi Tawil, Kathryn R Wagner, Johanna I Hamel, et al.
Pageof 37